



---

## **Bayer creates a provision in the amount of 275 million euros for civil antitrust actions**

---

**Leverkusen, December 6, 2005**

Bayer has reached agreements in principle to settle a number of the civil antitrust actions claiming damages which are currently pending against it in the United States and which are related to the Polymers-Business and described in its Interim Reports of 2005 and in other disclosures. Certain of these agreements, once finalized, are subject to court approval.

Bayer will create a provision in the fourth quarter of 2005 in the amount of 275 million euros in respect of the actions covered by these agreements.

As the financial risk associated with the remaining actions is currently not quantifiable, it was not possible to take accounting measures with respect to these litigations as a whole. Bayer expects that, in the course of the remaining governmental proceedings and civil actions, additional expenses will become necessary that may also be of material importance to the company.

Bayer AG  
D-51368 Leverkusen  
Germany

ISIN: DE0005752000  
WKN: 575 200

Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Paris; Swiss Exchange; London; Antwerpen; Brüssel; Amsterdam; Luxemburg; Mailand; Madrid; New York

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ilia Kürten (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

Judith Nestmann (+49-214-30-66836)

**Forward-looking statements**

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



## Ad-hoc-Message

---

### **Bayer's earnings advance strongly in first quarter**

- Underlying EBIT from continuing operations up by 50.1 % to EUR 1,142 million
  - Full-year 2005 forecasts confirmed
- 

**Leverkusen, April 29, 2005.** The Bayer Group achieved strong increases in sales and earnings in the first quarter of 2005. According to preliminary figures, sales from continuing operations grew by 15.7 percent to EUR 6,704 million (Q1 2004: 5,792 million). Currency- and portfolio-adjusted sales expanded by 9.3 percent. The economy remained robust, driven primarily by the United States and Asia. The operating result (EBIT) from continuing operations before special items improved by 50.1 percent to EUR 1,142 million (Q1 2004: EUR 761 million).

Even after special items of minus EUR 138 million, EBIT grew by a substantial 33.2 percent to EUR 1,004 million (Q1 2004: EUR 754 million). The non-operating result came to minus EUR 131 million (Q1 2004: minus EUR 116 million), while net income – which also includes net earnings from discontinuing operations – grew by 55.6 percent to EUR 652 million (Q1 2004: EUR 419 million). Earnings per share were EUR 0.89 (Q1 2004: EUR 0.57).

All subgroups contributed to Bayer's gratifying first-quarter performance – particularly MaterialScience, where currency- and portfolio-adjusted sales advanced by 34 percent and underlying EBIT roughly tripled year on year. Despite difficult climatic conditions in Europe and Latin America, underlying EBIT of Bayer CropScience also improved compared to the high level of the previous year. Underlying EBIT of Bayer HealthCare also edged forward, as the subgroup more than offset the effects of the decline in sales of the antibiotic Cipro<sup>®</sup> due to its patent expiration in the United States and the special charges in connection with the Roche OTC acquisition.

For 2005 Bayer is targeting an increase of more than 5 percent in currency- and portfolio-adjusted sales from continuing operations, to over EUR 25 billion. The company also reaffirms its target of improving EBIT from continuing operations before special items by around 20 percent despite the renewed rise in raw material costs.

**Note:** *The report for the first quarter of 2005 is scheduled for publication at 7:30 a.m. CEST on May 10, 2005.*

Investor Relations Contacts:

Dr. Alexander Rosar (+49-214-30-81013)  
Dr. Juergen Beunink (+49-214-30-65742)  
Peter Dahlhoff (+49-214-30-33022)  
Ute Krippendorf (+49-214-30-33021)  
Ilia Kürten (+49-214-30-35426)  
Judith Nestmann (+49-214-30-66836)

**Forward-looking statements**

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Ad-hoc publication pursuant to section 15 of  
the German Securities Trading Act

Bayer AG  
Investor Relations  
51368 Leverkusen  
Germany  
[www.investor.bayer.com](http://www.investor.bayer.com)

---

## **Bayer significantly improves both sales and earnings**

---

**Leverkusen, March 2, 2005**

Provisional figures for fiscal 2004:

- Currency- and portfolio-adjusted sales rise by 9 percent
  - EBIT before special items up 53 percent to EUR 2.2 billion
  - Management Board proposes dividend of EUR 0.55 per share for 2004
- 

The Bayer Group significantly improved both sales and earnings in fiscal 2004 and thus exceeded its targets. Provisional and as yet unaudited figures show that sales grew by 4.2 percent to EUR 29,758 million (2003: EUR 28,567 million). Adjusted for the effects of currency translations and portfolio changes, sales rose by 9.1 percent. The operating result (EBIT) before special items increased by 53.1 percent to EUR 2,244 million (2003: EUR 1,466 million). Contributing factors, apart from a marked upturn in business, were the company's efforts to reduce costs and increase efficiency. Bayer was thus able to more than offset the sharp rise in raw material prices, negative currency effects and expiration of the U.S. patent for Cipro.

EBIT after special items improved to plus EUR 1,808 million from minus EUR 1,119 million in 2003. Earnings before interest, taxes, depreciation and amortization (EBITDA) rose by 14.2 percent to EUR 4,130 million (2003: EUR 3,616 million). Before special items, EBITDA increased by 9.1 percent to EUR 4,494 million (2003: EUR 4,118 million). Net income came to plus EUR 603 million (2003: minus EUR 1,361 million). Gross cash flow increased by 12.1 percent to EUR 3,210 million.

To ensure that Bayer's shareholders participate in this success, a dividend for fiscal 2004 of EUR 0.55 (2003: EUR 0.50) per share will be recommended to the Annual Stockholders' Meeting, subject to the approval of the Supervisory Board.

The 2004 figures still include Lanxess AG, which was spun off on January 28, 2005, and the blood plasma business that is to be sold to a U.S. investor group. Closing of this transaction is expected during the first half of 2005. Bayer will provide further details of the Group's performance in fiscal 2004 at its Spring Financial News Conference to be held in Leverkusen on March 15.

Bayer AG  
D-51368 Leverkusen  
Germany

ISIN: DE0005752000

WKN: 575 200

Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Paris; Swiss Exchange; London; Antwerpen; Brüssel; Amsterdam; Luxemburg; Mailand; Madrid; New York

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ute Krippendorf (+49-214-30-33021)

Ilia Kürten (+49-214-30-35426)

Judith Nestmann (+49-214-30-66836)

**Forward-looking statements**

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.



Ad-hoc publication pursuant to section 15 of  
the German Securities Trading Act

Bayer AG  
Investor Relations  
51368 Leverkusen  
Germany  
[www.investor.bayer.com](http://www.investor.bayer.com)

---

## **Bayer AG: LANXESS spin-off legally effective**

---

**Leverkusen, January 28, 2005**

The spin-off of the LANXESS subgroup took legal effect on January 28, 2005 upon its entry in the commercial register for Bayer AG. The chemicals and polymers activities of the LANXESS subgroup relating to the spun-off assets and liabilities have thus been legally transferred from Bayer AG to LANXESS AG. In return, all the shares of LANXESS AG are being allotted to Bayer AG stockholders in the ratio of one LANXESS share for every ten Bayer shares held. For technical reasons the allotment will not take place until after the close of trading today. The number of LANXESS shares to be allotted to each Bayer stockholder is dependent on the number of Bayer shares held by such stockholder at that time.

All the shares of LANXESS AG are to be admitted on January 28, 2005 to the Prime Standard sub-segment of the official market segment (Amtlicher Markt) of the Frankfurt Stock Exchange. Trading in the shares of LANXESS AG is scheduled to commence on January 31, 2005. From that day forward, Bayer AG shares are to be quoted "ex-spin-off". On January 28, 2005 trading in LANXESS AG shares is not yet possible and Bayer shares will continue to be traded "cum LANXESS".

Bayer AG  
D-51368 Leverkusen  
Germany

ISIN: DE0005752000

WKN: 575 200

Listing: Official market Frankfurt sub-segment entailing additional post-admission obligations (Prime Standard) Berlin-Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart; Paris; Swiss Exchange; London; Antwerpen; Brüssel; Amsterdam; Luxemburg; Mailand; Madrid; New York

**This ad-hoc publication is neither an offer to sell nor an invitation to purchase any type of securities. In particular, it is not an offer for the sale of securities in the United States. Securities may not be offered or sold in the United States except with prior registration or with an exemption from registration under the U.S. Securities Act of 1933, as amended. Neither LANXESS AG nor Bayer AG intends to register any securities of LANXESS AG in the United States or to conduct a public offering of securities in the United States or any other jurisdiction.**

Bayer Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ute Krippendorf (+49-214-30-33021)

Ilia Kürten (+49-214-30-35426)

Judith Nestmann (+49-214-30-66836)

**Forward-looking statements**

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.